Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide in multiple myeloma.

Ramón García-Sanz1

  • 1Department of Haematology, University Hospital of Salamanca, Paseo de San Vicente, 58-182, Salamanca, 37007, Spain. rgarcias@usal.es

Expert Opinion on Pharmacotherapy
|January 26, 2006
PubMed
Summary

Thalidomide offers a new treatment for multiple myeloma, a difficult bone marrow cancer. It shows effectiveness in relapsed and refractory cases, despite its mechanism of action requiring further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptomic landscape of peripheral T cells following CAR-T cell therapy in diffuse large B cell lymphoma.

Cancer immunology, immunotherapy : CII·2026
Same author

Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

Blood neoplasia·2026
Same author

Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

British journal of haematology·2026
Same author

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Blood advances·2026
Same author

Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers.

Blood cancer discovery·2026
Same author

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance.

International journal of cancer·2026

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma is an incurable and challenging bone marrow cancer.
  • Traditional treatments like chemotherapy and transplants offer limited success.
  • There is a critical need for novel therapeutic agents.

Purpose of the Study:

  • To review current knowledge on thalidomide for multiple myeloma treatment.
  • To focus on the drug's mechanisms of action, clinical outcomes, and side effects.

Main Methods:

  • Literature review of thalidomide in multiple myeloma therapy.
  • Analysis of clinical results and adverse events.
  • Exploration of potential mechanisms of action.

Main Results:

  • Thalidomide introduced a new therapeutic approach in 1999.
  • Demonstrated efficacy in refractory and relapsed multiple myeloma.
  • Effective even in advanced stages of the disease.

Conclusions:

  • Thalidomide is a significant advancement in multiple myeloma treatment.
  • Further research is needed to fully elucidate its mechanism of action.
  • Thalidomide provides a valuable option for patients with limited therapeutic choices.

Related Experiment Videos